- Home
- JKHY vs KYMR Comparison
JKHY vs KYMR Comparison
Compare JKHY & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JKHY | KYMR |
|---|---|---|
| Founded | 1976 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 10.6B |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JKHY | KYMR |
|---|---|---|
| Price | $166.05 | $120.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 26 |
| Target Price | ★ $197.25 | $107.72 |
| AVG Volume (30 Days) | ★ 887.9K | 625.1K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | ★ 19.31 | N/A |
| EPS | ★ 5.41 | N/A |
| Revenue | ★ $1,536,603,000.00 | $39,211,000.00 |
| Revenue This Year | $8.03 | $10.61 |
| Revenue Next Year | $6.39 | $8.17 |
| P/E Ratio | $30.51 | ★ N/A |
| Revenue Growth | ★ 7.37 | N/A |
| 52 Week Low | $121.04 | $39.84 |
| 52 Week High | $193.39 | $130.05 |
Technical Indicators
Market Signals| Indicator | JKHY | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 65.13 | 63.17 |
| Support Level | $163.89 | $76.40 |
| Resistance Level | $172.84 | $130.05 |
| Average True Range (ATR) | 4.84 | 4.56 |
| MACD | 0.58 | 1.28 |
| Stochastic Oscillator | 77.84 | 78.05 |
Price Performance
Historical ComparisonAbout JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, including electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.